Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
CD70 VHH - 01 | Lead | Hematological Malignancy | Non-hodgkin lymphoma |
5e5 of 293 CAR cells transfected with anti-CD27 Ligand-scFv were stained with 100 μL of 3 μg/mL of Alexa Fluor 555-Labeled Human CD27 Ligand Protein, His Tag (Cat. No. CDL-HA245) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A), Alexa 555 signal was used to evaluate the binding activity (QC tested).
Immobilized Anti-CD27 Ligand Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human CD27 Ligand, His,Flag Tag (Cat. No. CDD-HF2D4) with a linear range of 0.039-0.156 μg/mL (QC tested).
The purity of FITC-Labeled Human CD27 Ligand, His,Flag Tag (Cat. No. CDD-HF2D4) is more than 85% and the molecular weight of this protein is around 55-74 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Cusatuzumab | ARGX-110; JNJ-4550 | Phase 2 Clinical | Argenx Se | Myelodysplastic Syndromes; Neoplasms; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
PRO-1160 | PRO-1160 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Nasopharyngeal Carcinoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD70 Targeted CAR-T Cells Therapy(UTC Therapeutics) | Phase 2 Clinical | UTC Therapeutics Inc | Solid tumours; Urologic Neoplasms; Lymphoma | Details | |
MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
GD2/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR PSMA/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
SEA-CD70 | SEA-CD70 | Phase 1 Clinical | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details | |
BR-108 | BR-108 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Leukemia; Hematologic Neoplasms | Details |
ARX-305 | ARX-305; NCB-002 | Phase 1 Clinical | Neoplasms | Details | |
Chimeric Antigen Recertor Treatment Targeting CD70(Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Leukemia, T-Cell | Details | |
CAR T-cell Therapy Directed to CD70(St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital | Hematologic Neoplasms; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Myeloid, Acute | Details | |
CD70-CART(Hrain) | HR010; HR-010 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Renal Cell | Details |
Anti-CD19/CD70 NK cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, Non-Hodgkin | Details | |
CD70 CAR-T cell therapy (Chongqing Precision Biotech) | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Neoplasms; Genital Neoplasms, Female; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details | |
CTX-130 | CTX-130 | Phase 1 Clinical | Crispr Therapeutics Ag | Carcinoma, Renal Cell; Lymphoma, T-Cell | Details |
IMM-40H | IMM-40H; IMM40H | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
ALLO-316 | ALLO-316 | Phase 1 Clinical | Cellectis Sa | Carcinoma, Renal Cell | Details |
C-4-29 | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Carcinoma, Renal Cell; Multiple Myeloma | Details | |
Cord Blood-derived CAR NK Cells Targeting CD19/CD70(Tongji University) | Tongji University | Details | |||
Cusatuzumab | ARGX-110; JNJ-4550 | Phase 2 Clinical | Argenx Se | Myelodysplastic Syndromes; Neoplasms; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
PRO-1160 | PRO-1160 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Nasopharyngeal Carcinoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD70 Targeted CAR-T Cells Therapy(UTC Therapeutics) | Phase 2 Clinical | UTC Therapeutics Inc | Solid tumours; Urologic Neoplasms; Lymphoma | Details | |
MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
GD2/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR PSMA/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
SEA-CD70 | SEA-CD70 | Phase 1 Clinical | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details | |
BR-108 | BR-108 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Leukemia; Hematologic Neoplasms | Details |
ARX-305 | ARX-305; NCB-002 | Phase 1 Clinical | Neoplasms | Details | |
Chimeric Antigen Recertor Treatment Targeting CD70(Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Leukemia, T-Cell | Details | |
CAR T-cell Therapy Directed to CD70(St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital | Hematologic Neoplasms; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Myeloid, Acute | Details | |
CD70-CART(Hrain) | HR010; HR-010 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Renal Cell | Details |
Anti-CD19/CD70 NK cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, Non-Hodgkin | Details | |
CD70 CAR-T cell therapy (Chongqing Precision Biotech) | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Neoplasms; Genital Neoplasms, Female; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details | |
CTX-130 | CTX-130 | Phase 1 Clinical | Crispr Therapeutics Ag | Carcinoma, Renal Cell; Lymphoma, T-Cell | Details |
IMM-40H | IMM-40H; IMM40H | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
ALLO-316 | ALLO-316 | Phase 1 Clinical | Cellectis Sa | Carcinoma, Renal Cell | Details |
C-4-29 | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Carcinoma, Renal Cell; Multiple Myeloma | Details | |
Cord Blood-derived CAR NK Cells Targeting CD19/CD70(Tongji University) | Tongji University | Details |
This web search service is supported by Google Inc.